

Notable Foundation Formulary Changes for January 2026

The formulary changes listed below will take effect January 1st, 2026. Please refer to the member portal for more specific information.

Moving to Preferred Brand Status

Medication	Used to Treat	Comments
ADALIMUMAB-AACF	Inflammatory Conditions	Humira Biosimilar
ADALIMUMAB-ADBМ	Inflammatory Conditions	Humira Biosimilar
ADALIMUMAB-FKJP	Inflammatory Conditions	Humira Biosimilar
EMGALITY	Migraine Prevention	
HADLIMA	Inflammatory Conditions	Humira Biosimilar
SIMLANDI	Inflammatory Conditions	Humira Biosimilar

Moving to Higher Tier

Medication	Used to Treat	Formulary Alternatives at Lower Tier
KLOR-CON	Low Potassium	Potassium Chloride Tab ER
SSD 1% CREAM	Wound Infections and Burns	Silver Sulfadiazine Cream 1%

REMOVAL from Formulary

Medication	Used to Treat	Formulary Alternatives
AJOVY	Migraine Prevention	Aimovig, Emgality, Nurtec, Qulipta
BRILINTA	Blood Clot Prevention	Ticagrelor
COPAXONE	Multiple Sclerosis	Avonex Pen, Avonex Prefilled, Betaseron, Glatiramer Acetate, Glatopa, Teriflunomide
FLUTICASONE-SALMETEROL HFA (Authorized Generic to Advair HFA)	Respiratory Disorders	Advair HFA
GLEEVEC	Cancer and Blood Disorders	Imatinib
NAMZARIC	Alzheimer Disease	Memantine-Donepezil Cap ER 24HR
ONETOUCH TEST STRIPS & SUPPLIES	Diabetes	Contour, Contour Next
SPRYCEL	Leukemia	Dasatinib
STELARA	Inflammatory Conditions	Steqeyma, Yesintek